<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412696</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HD078515-01A1</org_study_id>
    <nct_id>NCT02412696</nct_id>
  </id_info>
  <brief_title>Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)</brief_title>
  <acronym>PAP-SAP</acronym>
  <official_title>Placental Role in Mediating Adverse Outcomes in Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Miriam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women and Infants Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Miriam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is testing the hypothesis of whether continuous positive airway pressure (CPAP)&#xD;
      therapy improves placental histopathology and secretory function. The main aims of the study&#xD;
      are to identify shared mechanisms between obstructive sleep apnea and preeclampsia, both&#xD;
      common highly morbid conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited from multiple community and hospital-based practices that care for&#xD;
      pregnant women. Subjects will be given a physical exam, have measurements taken, answer&#xD;
      questionnaires and then will be screened using a home sleep apnea test (HSAT) Type III&#xD;
      device. Those diagnosed with Obstructive Sleep Apnea will then be randomized to one of two&#xD;
      groups (below).&#xD;
&#xD;
      Both groups will have:&#xD;
&#xD;
        1. blood testing for placenta-secreted circulating markers&#xD;
&#xD;
        2. placental histopathological and immunohistochemistry examination of placental expression&#xD;
           of markers.&#xD;
&#xD;
      Both groups will answer sleep and mood questionnaires, have blood pressure, blood glucose and&#xD;
      activity / sleep watch monitoring and will receive an educational session on pregnancy&#xD;
      health.&#xD;
&#xD;
      Randomization groups include:&#xD;
&#xD;
        1. Nasal dilator strips: Participants receiving nasal dilator strips will be monitored by&#xD;
           need for refill of supplies and periodic phone calls.&#xD;
&#xD;
        2. CPAP + nasal dilator strips: Subjects randomized to positive airway pressure (PAP)&#xD;
           therapy will receive auto-titrating PAP. Pressure requirements will be monitored&#xD;
           remotely and pressure modified as needed. PAP adherence will be determined subjectively&#xD;
           and objectively. This group will also receive nasal dilator strips as described above.&#xD;
&#xD;
      All subjects will receive small gift incentives such as baby-related items. Monetary&#xD;
      incentives will also be issued at data collection points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alterations in circulating placenta-secreted markers.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Placenta secreted markers that have been linked to preeclampsia as well as angiogenic and anti-angiogenic markers will be measured longitudinally during the course of pregnancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in placental histopathology for markers of malperfusion and placental expression of markers</measure>
    <time_frame>Placenta collected at time of delivery</time_frame>
    <description>Placental morphology and histopathology will be examined by 3 perinatal pathologists, blinded to each other's reading and to intervention arm. Immunohistochemistry will be used to examine placental expression of certain markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Ambulatory mean diurnal and nocturnal blood pressure measurements</measure>
    <time_frame>Prior to randomization, then at approximately 3 months, and 6 months later</time_frame>
    <description>A 24 blood pressure monitor will be used to measure changes in daytime and nighttime average blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in a composite of adverse pregnancy outcomes</measure>
    <time_frame>8 months, delivery and 2 weeks postpartum</time_frame>
    <description>Pregnancy outcomes defined as gestational hypertension, gestational diabetes and preterm birth (birth prior to 37 completed weeks of pregnancy will be analyzed as a composite outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Pregnancy</condition>
  <condition>Obesity</condition>
  <condition>Preeclampsia</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Positive Airway Pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Positive airway pressure and nasal dilator strips during sleep.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Dilator Strips</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal dilator strips during sleep.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positive Airway Pressure</intervention_name>
    <description>Auto-titrating PAP + nasal dilator strips during sleep</description>
    <arm_group_label>Positive Airway Pressure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal Dilator Strips</intervention_name>
    <description>Nasal dilator strips</description>
    <arm_group_label>Nasal Dilator Strips</arm_group_label>
    <arm_group_label>Positive Airway Pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant snorers without obstructive sleep apnea, have a BMI &gt;30 kg/m2 at recruitment&#xD;
&#xD;
          -  &gt;18 years of age&#xD;
&#xD;
          -  &lt;13 completed weeks of gestation (confirmed by last menstrual period or early&#xD;
             pregnancy dating ultrasound during qualification)&#xD;
&#xD;
          -  Intention to reside locally and deliver at Women and Infants Hospital of Rhode Island&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to meet inclusion criteria, Incompetent cervix / cerclage (likelihood of severe&#xD;
             preterm delivery affecting study aims)&#xD;
&#xD;
          -  Inability to tolerate PAP therapy&#xD;
&#xD;
          -  Serious physical or mental illness or condition that would affect participation&#xD;
&#xD;
          -  Drowsy driving&#xD;
&#xD;
          -  Severe hypoxemia on sleep study&#xD;
&#xD;
          -  Advanced cardiac disease or arrhythmias that may benefit from PAP therapy&#xD;
&#xD;
          -  Chronic lung disease and / or respiratory failure.&#xD;
&#xD;
          -  Twin pregnancies&#xD;
&#xD;
          -  Fetuses with congenital anomalies&#xD;
&#xD;
          -  Severe hypertension at enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghada Bourjeily, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Miriam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Miriam Hospital</investigator_affiliation>
    <investigator_full_name>Ghada Bourjeily</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>placental morphology</keyword>
  <keyword>CPAP</keyword>
  <keyword>placental secretory function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

